80 results about "Ischaemia reperfusion" patented technology

The invention discloses a myocardial ischemia reperfusion injury animal model construction method and application thereof in the technical field of model animal preparation. The method comprises the steps of hypertension and hyperlipidemia pretreatment, standardized ischemia-reperfusion operation, immune microenvironment regulation and control and model evaluation and verification. According to the invention, model construction is carried out on an integrated model operation table, so that a standardized ischemia-reperfusion process is realized, reproducibility of a myocardial injury degree and an immune cell infiltration rule of the model is realized, and suitability of the model and nano-drug research is enhanced; and a reliable tool is provided for research and development of targeted drugs such as immune cell membrane coated nanoparticles.

The invention belongs to the field of application materials, and particularly relates to Ber-ApoEVs and preparation and application thereof.The Ber-ApoEVs comprise ApoEVs and Ber supported by the ApoEVs, the ApoEVs are bone marrow mesenchymal stem cell-derived apoptosis vesicles, and the Ber is berberine and a derivative thereof. Researches show that brand new Ber-ApoEVs play a synergistic neuroprotective role in the aspects of regulating and controlling polarization of microglial cells, release of inflammatory factors, p38 / MAPK signals and the like, neuroinflammation caused by retinal ischemia reperfusion (IR) can be relieved, retinal neuron apoptosis can be inhibited, and the Ber-ApoEVs can be used for treating glaucoma.

The invention discloses a pharmaceutical composition and application thereof in preparation of a medicine for treating sudden deafness, pharmacodynamic data shows that all components of the composition have a synergistic effect, the solubility and bioavailability of the composition in water can be remarkably improved, and the pharmaceutical composition can be used for treating sudden deafness. Through an oral administration mode, the hearing threshold of cochlear ischemia reperfusion model animals can be remarkably reduced, release of inflammatory factors such as serum IL-1beta and TNF-alpha is inhibited, oxidative stress is relieved (the malondialdehyde level is reduced), so that multi-target synergistic treatment of sudden deafness is realized, the effect is remarkable, the defects that an existing drug is single in target and inconvenient to administrate are overcome, and the application prospect is wide. The important clinical application value is realized.

A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases. Experiments in animal models of ischemia-reperfusion (UIRI)-induced renal fibrosis, unilateral ureteral obstruction (UUO)-caused kidney fibrosis and idiopathic pulmonary fibrosis show that a PDE5 inhibitor such as tadalafil, sildenafil and vardenafil can significantly inhibit the expression of multiple fibrosis iconic proteins such as fibronectin, collagen I, renal injury molecule-1, and α-skeletal muscle actin in UIRI and UUO renal fibrosis lesions, improves glomerulopathy, degree of renal tubular distension, renal interstitial collagen fiber deposition and inflammatory cell infiltration, reduces the fibrotic area within the lesion, and significantly inhibits the progression of renal fibrosis; and the PDE5 inhibitor can significantly improve smooth muscle proliferation and inflammatory cell infiltration in bronchioles and pulmonary arterioles of idiopathic pulmonary fibrosis lesion, improve damage condition of alveolar tissue, and significantly inhibit the progression of pulmonary fibrosis.

The application relates to the field of myocardial ischemia-reperfusion injury drugs, and discloses application of Gualou Xiebai Baijiu decoction in preparation of myocardial ischemia-reperfusion injury drugs. The myocardial ischemia-reperfusion injury drugs inhibit the GSK-3beta / Drp1-mediated mitochondrial fission pathway by targeting Akt protein, maintain the dynamic balance of mitochondrial dynamics, and play a myocardial protection role. The drugs can promote Akt phosphorylation activation, inhibit GSK-3beta activity, down-regulate Drp1 protein Ser616 site phosphorylation, up-regulate Ser637 site phosphorylation, reduce Drp1 translocation and aggregation to the outer membrane of mitochondria, and simultaneously up-regulate the expression of mitochondrial fusion proteins Mfn1 and Mfn2. The drugs can maintain the structural integrity of mitochondria, improve the mitochondrial membrane potential and ATP content, improve myocardial cell energy metabolism, regulate the expression of apoptosis-related proteins to inhibit myocardial cell apoptosis, improve the cardiac systolic function after ischemia-reperfusion, reduce the myocardial infarction area, reduce the serum myocardial injury marker level, and regulate the oxidative stress state.

The invention relates to application of an mRNA-loaded exosome in preparation of a medicine for preventing and / or treating myocardial ischemia reperfusion, and belongs to the technical field of biological medicines. The invention provides an application of an exosome loaded with mRNA (messenger ribonucleic acid) as shown in SEQ ID NO.1 in preparation of a medicine for preventing and / or treating myocardial ischemia reperfusion. The prepared exosome or the exosome and melatonin are combined for administration, myocardial ischemia reperfusion injury can be effectively prevented and / or treated, and the exosome has the advantages of being good in treatment effect, high in biological safety, low in side effect and high in targeting performance and systematicness.

The invention discloses an aromatic alkylamine ferroptosis inhibitor based on a butylphthalide structure and a preparation method and application thereof. The chemical structural formula of the ferroptosis inhibitor is shown as a formula 1 or a formula 2. The ferroptosis inhibitor can inhibit ferroptosis caused by a ferroptosis inducer and can reduce the level of active oxygen in cells. Nerve injury caused by cerebral ischemia reperfusion can be relieved, and symptoms of neurological diseases such as Alzheimer's disease and Parkinson's disease can be relieved; compared with a ferroptosis inhibitor Ferrostatin-1, the aryl alkyl amine compound disclosed by the invention has better metabolic stability and is suitable for in-vivo drug effect evaluation. Therefore, the novel aryl alkyl amine compound provided by the invention has a very good application value in treatment of neurological diseases related to ferroptosis.

The invention relates to application of serum mucoid or Tax1 binding protein 1 in preparation of a medicine for treating medicine-induced liver injury or organ ischemia-reperfusion injury. Experiments prove that by using an adeno-associated virus (AAV) carrying an Orm2 gene, ORM2 recombinant protein or knocking down a TAX1BP1 gene, liver injury and liver failure, ischemia reperfusion injury of the liver, ischemia reperfusion injury of the kidney and ischemia reperfusion induction of intestines induced by APAP treatment can be effectively relieved, and the application has the advantages that the liver injury and liver failure, the ischemia reperfusion injury of the kidney and the ischemia reperfusion induction of the intestine can be effectively relieved; and a new target spot and a new treatment method are provided for treating the ferroptosis-related organ injury.

The invention relates to the technical field of biomedicine, in particular to a preparation method of sequential targeting mesoporous manganese oxide nano-enzyme and application of the sequential targeting mesoporous manganese oxide nano-enzyme in treatment of ischemia reperfusion induced acute kidney injury. Adding a potassium permanganate solution into the silicon dioxide nanoparticle dispersion liquid under ultrasonic waves, and carrying out alkali etching to obtain mesoporous manganese oxide nanoparticles (HMN); and after surface amination modification, connecting with a mixed PEG spacer layer, and reacting with thiolated SS31 and azidoacyl hyaluronic acid to obtain the nano-enzyme. The preparation can effectively penetrate through a damaged glomerulus filtration barrier and is passively enriched in a damaged kidney, damaged renal tubular epithelial cells over-express CD44 receptor mediated hyaluronic acid modified nano-particle endocytosis is enhanced, SS31 modified nano-particles achieve lysosome escape mitochondrial targeting in cells, the level of active oxygen in mitochondria can be reduced, and the activity of the mitochondria can be improved. The mitochondrial function is recovered, the renal function and tissue pathological injury are improved, and accurate anti-oxidation treatment on the acute kidney injury is realized.

The invention discloses an intelligent cerebral apoplexy cell state recognition method based on Cellpose and fluorescence image analysis and application of the intelligent cerebral apoplexy cell state recognition method in drug effect screening. The intelligent cerebral apoplexy cell state recognition method comprises the following steps: S1, establishing a cerebral apoplexy ischemia reperfusion cell model; s2, adding a nitrite fluorescent probe into the cells subjected to ischemia reperfusion treatment to obtain a fluorescent microscopic image of the cells; s3, importing the fluorescence microscopic image into a Cellpose model for cell segmentation, and obtaining an ROI region of each cell; s4, extracting fluorescence intensity characteristics and cell morphological characteristics in the ROI region of each cell; and S5, inputting the extracted multi-dimensional features into a classification model for cell state recognition, so as to distinguish a single cell into three states of health, mild injury or serious injury. According to the method, a complete link of image acquisition-Cellpose analysis-feature extraction-state discrimination-drug effect evaluation is constructed, and the practical application value of a deep learning image algorithm in disease model research and drug screening scenes is expanded.

The present invention discloses a method for constructing a mouse tail distal ischemia preconditioning renal protection model and its application, which belongs to the field of ischemia preconditioning technology, and its purpose is to solve the technical problem of poor stability and reliability of renal protection experimental results in the prior art. It is by respectively constructing a tail distal ischemia preconditioning group, a septic acute kidney injury model group and a tail control group; when constructing the tail distal ischemia preconditioning group, a tourniquet is tied on the mouse tail, and blood flow is restored by blocking blood flow and repeating the cycle; and blood and kidney tissue of mice in each group are collected for testing, serum creatinine and serum urea nitrogen indicators are measured, renal tubular pathological damage is assessed, and the expression level of renal reactive oxygen species is assessed. This method proves that tail ischemia reperfusion preconditioning can improve renal pathological damage and reduce renal tubular damage in septic acute kidney injury, inhibit renal oxidative stress in septic acute kidney injury, and reduce the inflammatory response of septic acute kidney injury.

The invention discloses an application of an lncRNA-MALAT1 / miR-145 / BNIP3 regulation axis in preparation of a medicine for treating hemorrhagic shock ischemia reperfusion intestinal injury. In existing treatment, conventional liquid resuscitation easily causes serious inflammation and pathological apoptosis, the intestinal barrier repair effect is limited, and the molecular mechanism is not completely clarified. The invention discloses that a regulatory axis participates in an intestinal injury process through a ceRNA mechanism (MALAT1 is used as miR-145 sponge to inhibit regulation of BNIP3 and mediate controlled programmed cell death instead of pathological apoptosis), and provides a new molecular target for treatment. The medicine aiming at the regulation shaft can relieve inflammatory response, reduce pathological apoptosis and promote intestinal barrier repair, and has a good application prospect.

Provided is a pharmaceutical composition and application thereof, specifically, said pharmaceutical composition comprises: salvianolic acid B as a first active ingredient; and ginsenoside Rg1 as a second active ingredient, and the weight ratio of the first active ingredient to the second active ingredient being 5:(1-4.5). The pharmaceutical composition has a better active-ingredient proportion than the prior art, has a better therapeutic efficacy in preventing and / or treating ischemic diseases, and ischemia-reperfusion tissue or organ damage, and can be used for treating ischemia and / or ischemia-reperfusion damage of different tissues and organs.

The invention discloses application of 2-fluorofucose in preparation of a medicine for relieving acute kidney injury, and belongs to the technical field of biology. In-vitro cell experiments and animal experiments prove that 2-fluorofucose can inhibit core fucosylation, competitively inhibit the activity of fucosyltransferase, down-regulate the expression of FUT8 and reduce the core fucosylation level in kidney tissues and renal tubular epithelial cells; by inhibiting core fucosylation, effectively reversing EMT phenotypic transformation induced by hypoxia reoxygenation or ischemia reperfusion, up-regulating E-cadherin expression, down-regulating alpha-SMA and Snail expression and reducing cell migration ability, phosphorylation activation of an ERK pathway is remarkably inhibited, and downstream inflammatory factor release and cell injury signal transduction are blocked, so that the ERK pathway can be used for inhibiting ERK pathway phosphorylation activation. The invention provides application of 2-fluorofucose to preparation of a medicine for relieving acute kidney injury. The invention provides a new choice for treating acute kidney injury, has the outstanding advantages of remarkable curative effect, high safety and the like, and has a wide application prospect.

Disclosed are an aromatic alkylamine ferroptosis inhibitor based on a butylphthalide structure, a preparation method therefor, and an application thereof. The chemical structural formula of the ferroptosis inhibitor is as shown in formula (1) or formula (2). The ferroptosis inhibitor is capable of inhibiting ferroptosis caused by a ferroptosis inducer, and reduces the level of intracellular reactive oxygen species. The ferroptosis inhibitor reduces neurological damage caused by cerebral ischemia-reperfusion, and alleviates symptoms of neurological disorders such as Alzheimer's disease and Parkinson's disease. Compared to the ferroptosis inhibitor Ferrostatin-1, the arylalkylamine compound exhibits better metabolic stability and is suitable for in-vivo efficacy evaluation. Therefore, the novel arylalkylamine compound provided by the present invention demonstrates great application value in the treatment of ferroptosis-related neurological disorders.

The invention discloses an experimental method for relieving ferroptosis of cerebral apoplexy rats through tVNS, and relates to the technical field of nerve regulation and control. Comprising the following steps: S1, constructing a rat MCAO model, and constructing an SD rat right cerebral ischemia reperfusion model by adopting a suture method; s2, experiment grouping: randomly dividing experimental animals into (1) a false operation group: an SHAM group; (2) a cerebral ischemia reperfusion group: an MCAO group; (3) an ear vagus nerve electrical stimulation group after cerebral ischemia reperfusion: a tVNS group; and S3, performing ear vagus nerve electrical stimulation intervention. Ferroptosis related proteins such as GPX4, ACSL4 and FTH1 are detected through Western blot, it is proved that tVNS can improve stroke rat brain tissue ferroptosis, and clear molecular mechanism support is provided for intervention; the content of reduced glutathione and the content of malondialdehyde are respectively detected by using a GSH and MDA content detection kit, and the effectiveness of tVNS in the aspect of relieving ferroptosis is further verified.

The invention relates to application of a Nexilin overexpression recombinant vector in preparation of a medicine for treating MIRI, and belongs to the technical field of biological medicine. In order to solve the problems of insufficient intervention of a core pathological mechanism and limited treatment effect of the existing MIRI treatment means, the invention provides application of a Nexilin overexpression recombinant vector in preparation of MIRI treatment medicines. The invention proves that the Nexilin overexpression vector can effectively improve myocardial ischemia-reperfusion injury for the first time, can remarkably improve the cardiac function of a mouse suffering from myocardial ischemia-reperfusion injury, reduce the content of myocardial injury markers, reduce the myocardial infarction area, restore the expression balance of Bcl-2 family proteins and inhibit myocardial cell apoptosis by up-regulating Bcl2 expression and down-regulating Bax expression, and has the advantages of being capable of improving myocardial ischemia-reperfusion injury, and being used for treating myocardial infarction. The protection effect on ischemia reperfusion myocardium is realized from multiple levels, and a brand new technical means and experimental basis are provided for clinically developing targeted therapeutic drugs for myocardial ischemia reperfusion injury.

The invention provides application of a product for supplementing Lrrc52 in preparation of a medicine for preventing and / or treating myocardial ischemia-reperfusion injury, and belongs to the technical field of biological medicine. The invention provides an application of a product for supplementing Lrrc52 as a medicine for preventing and / or treating myocardial ischemia-reperfusion injury, Lrrc52 protein is supplemented into a body, so that the apoptosis and necrosis degree of myocardial cells after myocardial ischemia-reperfusion can be effectively relieved, the pathological ventricular remodeling process is restrained, the cardiac fibrosis condition is relieved, the cardiac function is enhanced, and the myocardial ischemia-reperfusion injury can be prevented and treated. And therefore, heart-related diseases such as acute ischemia-reperfusion injury, pathological ventricular remodeling and heart failure can be prevented and treated. The invention clearly reveals the potential of overexpression Lrrc52 in the aspect of improving myocardial ischemia reperfusion injury for the first time, opens up a brand new drug research and development road and an action target for prevention and treatment of the disease, and shows extremely high medicinal value and significance.

The invention discloses an application of a compound in preparation of a medicine for treating cardiovascular diseases, the compound is SP3, and the structural formula is shown in the specification. The compound can obviously reduce the myocardial infarction area and ischemia area after myocardial ischemia reperfusion, has a myocardial protection effect, and particularly has a better effect on ischemic heart disease.

The invention discloses an application of biotin in preparation of a medicine for treating or preventing ischemia-reperfusion injury, the biotin is applied to intervention research of ischemia-reperfusion injury for the first time, and the protective effect of the biotin in a cell inflammation model and an animal ischemia-reperfusion model is systematically verified. A solid experimental foundation is laid for application of the method in treatment of related diseases such as lung ischemia reperfusion injury and ischemia reperfusion induced pulmonary arterial hypertension, and a brand-new intervention strategy is provided.

The present invention discloses the use of a compound in the preparation of a medicament for treating and / or preventing stroke. The compound is 2,3-dihydronaphtho[1,2-b]furan-4,5-dione, and the stroke includes acute ischemic stroke or ischemic reperfusion brain injury. The compound can effectively treat or prevent acute ischemic stroke by alleviating the acute brain injury caused by acute ischemic stroke or ischemic reperfusion, reducing the volume of cerebral infarction after acute ischemic stroke, alleviating cerebral edema after stroke, and improving neurological function after stroke.

The invention belongs to the technical field of biological medicines, and particularly discloses application of CDN1163 in preparation of a medicine for preventing or / and treating acute kidney injury. It is found for the first time that CDN1163 can relieve ischemia reperfusion induced AKI and reduce serum urea nitrogen and creatinine levels so as to play a role in protecting the kidney in the ischemia reperfusion induced AKI, and therefore the CDN1163 can be used for preparing the medicine for preventing or / and treating the acute kidney injury.

Provided is use of an HPCAL1 protein in enhancing cardiac function. The HPCAL1 protein can specifically bind to a recombinant β3-adrenergic receptor, and can be used as a β3-adrenergic receptor antagonist protein. It is found in animal experiments that by intravenously injecting recombinant mouse HPCAL1 with a certain concentration into an ischemia-reperfusion mouse model, the cardiac function of the mice can be effectively improved, and the ejection fraction of the mice is enhanced, indicating that the HPCAL1 protein can be used for enhancing the cardiac function and has potential medicinal value for treating cardiovascular diseases with cardiac function decline. Moreover, the HPCAL1 protein is a class of biomacromolecules with low toxicity, which solves the problem of high hepatic and renal toxicity of small molecule chemical drugs. Therefore, the HPCAL1 protein has relatively high application value.

The invention discloses an application of S100A9 in treatment of lung injury caused by liver ischemia reperfusion. A liver ischemia reperfusion animal model is utilized to find that S100A9 is closely related to lung injury caused by liver ischemia reperfusion. Lung injury caused by liver ischemia reperfusion can be effectively relieved by knocking out the S100A9 gene or inhibiting a downstream signal channel mediated by the S100A9. In addition, it is also found that the S100A9 expression level has very strong correlation with lung injury after liver transplantation by collecting patients clinically subjected to liver transplantation. Research results of the invention show that S100A9 is a diagnosis and treatment marker for lung injury caused by hepatic ischemia reperfusion.

The present invention provides a compound represented by formula A which can be used as a compound for preventing and treating oxidative damage caused by ischemia-reperfusion and a preparation method thereof. 10 As defined herein. The compounds of the present invention can react with peroxynitrite in the blood and further release carbon monoxide, thereby achieving anti-inflammatory and antioxidant effects. Tests of such compounds at the cellular level and in vivo level in mice show that they have achieved good therapeutic effects on a number of key evaluation indicators including brain near-death area, brain edema, blood-brain barrier, and neurological function scores, and have important potential for drug development.

The invention relates to the technical field of medicines, and particularly discloses application of 2-methylene butyrolactone in preparation of a medicine for resisting myocardial ischemia / reperfusion injury. The invention discloses a small molecule compound, namely, 2-methylene butyrolactone (Tulipalin A, TA), which can activate synthesis of glutathione and has a good protection effect. Research finds that Tulipalin A can reduce myocardial cell death, ROS accumulation and structural disorder caused by ischemia / reperfusion, improve the contraction function of human heart engineering tissue, relieve mouse heart injury and improve the heart function, and the Tulipalin A is further researched and developed into an anti-MI / R injury medicine.

The invention discloses a near-infrared tissue oxygen monitoring system which comprises a near-infrared blood oxygen probe, a circuit acquisition board and an upper computer system, the near-infrared blood oxygen probe is connected with the circuit acquisition board, and the circuit acquisition board is connected with the upper computer system; the near-infrared blood oxygen probe comprises two light source emitting devices and three light source receiving sensors which are connected with the circuit acquisition board, the two light source emitting devices are used for emitting infrared light with different wavelengths respectively, and the light source receiving sensors are used for receiving and transmitting optical signals; and the upper computer system is used for solving the current tissue oxygen value. The near-infrared tissue oxygen monitoring system can monitor the oxygen state of the biological local tissue counteracting ambient light, monitoring data are more accurate, the structure is simple and small, and the near-infrared tissue oxygen monitoring system is particularly suitable for ischemia reperfusion of small animals.

The invention discloses an application of picrogenin A in preparation of a medicine for treating ischemia-reperfusion injury. The invention proposes and verifies that the kuichnogenin A can inhibit ferroptosis to prevent and treat cerebral ischemia reperfusion injury for the first time, including greatly reducing the volume of cerebral infarction caused by cerebral ischemia reperfusion; the invention provides a plant-derived natural medicine for treating cerebral ischemia reperfusion injury, which has great application potential, and can be used for remarkably improving neurological function injury symptoms such as autonomous activity reduction, sensory motor function damage and motor coordination reduction caused by cerebral ischemia reperfusion, and the invention provides a plant-derived natural medicine for treating cerebral ischemia reperfusion injury.

The invention discloses application of a single fluorescent probe to simultaneous tracing of lipid droplets and mitochondria, the single fluorescent probe can also be used for detecting interaction between the mitochondria and the lipid droplets and cell polarity during ferroptosis caused by ischemia reperfusion (MIRI), and the single fluorescent probe is a fluorescent probe containing a BODIPY-indole structure. The single fluorescent probe can target lipid droplets and mitochondria at the same time and emit fluorescence of different colors, the excitation wavelength in the lipid droplets is 640 nm, so that the lipid droplets display dark red fluorescence, and the excitation wavelength in the mitochondria is 561 nm, so that the mitochondria display red fluorescence; therefore, the fluorescent probe disclosed by the invention can be used for monitoring dynamic changes of lipid droplets and mitochondria in living cells or living bodies in real time, and is of great significance to research of an MIRI treatment scheme.

This invention discloses the application of HY-Q67280 in the preparation of drugs for the prevention and / or treatment of myocardial ischemia / reperfusion injury, belonging to the field of biomedical technology. HY-Q67280 can activate the E3 ubiquitin ligase MARCH9. MARCH9 inhibits Drp1-dependent mitochondrial dysfunction, oxidative stress, and ferroptosis by targeting FXR1 degradation, reducing apoptosis and mitochondrial oxidative stress levels in mouse myocardial ischemia / reperfusion and rat neonatal primary cardiomyocytes after hypoxia / reoxygenation, and reducing mitochondrial division to improve mitochondrial function, thereby protecting against myocardial ischemia / reperfusion injury.